THE 2-MINUTE RULE FOR ABBV-744 IN THE TREATMENT OF DRUG-RESISTANT CANCERS

In Segment C, members will acquire ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the members are unable to tolerate the study drugs.For all circulation cytometry experiments, 10,000 cells for each replicate had been analyzed, and a f